Teva - Reasonable Start To 2018 Alleviates Immediate Concerns

Teva Pharmaceutical Industries (TEVA) has made great efforts in stabilising the business. In December of last year, I concluded that aggressive cost cuts provide relief to the business in combination with the dividend suspension and asset sales initiated by new and highly regarded CEO Kare Schultz.

Shares traded at $17 at the time as I was cautious to buy the dip despite the actions taken, recognising the deep problems which the company faces. Nonetheless, shares have rebounded nicely to $21 at this moment, driven by a relative solid start to 2018, alleviating some of the worst leverage concerns.

The Troubles

The issues for Teva have been largely self-inflicted and started with the $40 billion purchase of the generics business from Allergan (AGN). The debt incurred in connection to the deal, dramatic underperformance of the acquired activities, and generic competition for its own blockbuster Copaxone have been causing major headaches for investors.

READ FULL ARTICLE HERE